Login / Signup

Outcomes of weight-based vs. fixed dose of Pembrolizumab among patients with non-small cell lung cancer.

Lena ChaitesipaseutNina ShahThach-Giao TruongFang NiuPatrick ShinKavita SharmaJoshua SmithRita L Hui
Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2023)
These findings suggest that WBD of pembrolizumab may be as appropriate as FD for the treatment of lung cancer.
Keyphrases
  • advanced non small cell lung cancer
  • body mass index
  • physical activity
  • weight loss
  • type diabetes
  • weight gain
  • adipose tissue
  • insulin resistance